10x Genomics (TXG) Expected to Announce Quarterly Earnings on Thursday

10x Genomics (NASDAQ:TXG) is anticipated to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. 10x Genomics has set its FY 2025 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Stock Down 1.9 %

Shares of NASDAQ TXG opened at $12.07 on Wednesday. 10x Genomics has a 52 week low of $10.80 and a 52 week high of $48.42. The firm’s fifty day moving average is $14.52 and its 200 day moving average is $17.22. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -7.89 and a beta of 1.85.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on TXG. Leerink Partnrs cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. Citigroup decreased their target price on 10x Genomics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research report on Saturday, February 1st. JPMorgan Chase & Co. cut their price objective on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Finally, Barclays dropped their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.57.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.